%D8%A3%D8%A8%D8%B1%D9%8A%D9%85%D9%8A%D9%84%D8%A7%D8%B3%D8%AA%D8%A7%D9%BE%D8%B1%D9%85%DB%8C%D9%84%D8%A7%D8%B3%D8%AACategory:ApremilastApremilastApremilast%D8%A7%D9%BE%D8%B1%D9%85%DB%8C%D9%84%D8%A7%D8%B3%D8%AAApr%C3%A9milast%E3%82%A2%E3%83%97%E3%83%AC%E3%83%9F%E3%83%A9%E3%82%B9%E3%83%88Apremilast%D0%90%D0%BF%D1%80%D0%B5%D0%BC%D0%B8%D0%BB%D0%B0%D1%81%D1%82ApremilastApremilastApremilastQ2858961
about
P3781
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate to Severe Plaque PsoriasisQuality of Life and Echography Parameters of Nausea PsoriasisAn Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisStudy to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISEAn Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular EczemaPhase II Study With CC-10004 in Psoriatic ArthritisApremilast in the Treatment of Moderate to Severe AcneSafety and Efficacy of CC-10004 for Prurigo NodularisA Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet DiseaseTHE AP-GELP STUDY: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen PlanusAn Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital PsoriasisA Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life.Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.Apremilast and Moderate to Severe Chronic Hand DermatitisExpanded Access for CC-10004Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and EfficacyApremilast for RASStudy to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in SpainA Study Examining the Medication Apremilast as Treatment for Chronic ItchA Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of ApremilastStudy to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.Apremilast as Anti-pruritic Treatment in Patients With Prurigo NodularisApremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque PsoriasisTrial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing AlopeciaMonocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With ApremilastA Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in FranceApremilast in Psoriatic Arthritis in Real-life Clinical Practice in GreeceEvaluation of Add on Enstilar in Patients Using Otezla for PsoriasisA Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque PsoriasisApremilast 30 mg BID Combined With Dupilumab
P4844
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastA review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatologyTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyProposal for a new nomenclature of disease-modifying antirheumatic drugs.Advances in treating psoriasis.Apremilast for the treatment of psoriatic arthritis.Apremilast: first global approval.Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis.Novel treatments with small molecules in psoriatic arthritis.Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.New and emerging therapies in psoriasis.Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitisAn oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot studyPharmaceutical approval update
P921
Q170990-0A41D47C-D0EE-4B2F-8311-C6FCEE1C2DECQ179945-3547B332-BCA3-4BF3-84E0-D9A5ACFB1398Q511097-F4B84736-CC01-4793-9012-A8816985E245Q52849-D8380E0A-6830-4BEF-9C42-38A4A81F1ED6Q55781316-5D8E8696-06F8-4F09-A443-22232FE422BEQ55788663-7724C59B-B70E-4C2E-9C00-5A161EE3282AQ5621891-42A08DC9-E4E6-46E7-9D1C-2CFF02CC6C4FQ8277-AA6FEE1B-5DF2-4D01-BB44-B14859285521Q911427-06941612-2389-4979-9A76-29405FCC226A
P2176
Q61902320-A49497C9-B828-42FE-944D-CD3B54AF620AQ61904826-F2E4190C-8D8D-4388-8402-5FF0E7695B1FQ61906760-0953177E-4C5E-4F80-BA93-9D3F3F66C5BAQ61907024-4157795D-5CCB-413D-8770-5AC16A10CFDCQ61909295-72A366D2-48DD-4738-A3A1-062DC783EFB2Q61920577-EA51E429-63BE-40A0-A3C8-BDC48DFC9F97Q61938343-B9A747AD-E5AA-4707-9F20-B935AC912925Q61980751-4D0947C2-D16C-4200-8E70-596842F9AD40Q61980995-E3A50EAC-95BF-4057-AB98-57C7721FCF9BQ62024876-74CE9C95-7E26-4375-B6AF-7F9EA5BEE9C6Q62030742-5972D3EF-0F1C-4355-86B5-15A3B9C83D6FQ62030939-71A44FB2-8534-4E25-AFD2-1944E2933A2AQ62034267-AE6FBAA8-11B1-4C68-8588-0F3101991039Q62034798-440BBAEE-7717-4543-BE90-5A7510690A79Q62034934-9F822D42-D258-4EBB-9198-369CACC6F8C4Q62039755-42D0B9C6-706C-49F3-9662-445224918747Q62054161-C08410E7-CE2E-4B20-98A6-F5F2A38EA34BQ62812668-03350205-73D7-4ECB-A9DD-608682FADAB3Q63010589-2D0CBCA6-48CA-4931-8453-C330BE2A3298Q63316278-013934EA-B0DD-496C-886D-76F03FE8633CQ63341013-CCB227D8-E21C-40B3-A2C0-C057C7BF8C20Q63396164-087062D2-74C8-4FB0-8357-9EE664A5C383Q63397337-45248761-C349-4FEF-9800-CF80E200F899Q63400633-77272179-C6C6-4112-9497-FC1273CD48DEQ63402799-9B9E4A2A-B9CB-4569-9E1A-7AE2B0ADB3F6Q63403448-818CC98B-7A8F-4B65-81E3-4B9EEBD4DA21Q63593522-8A43D463-1493-48D6-AAFD-36C6ABAECBA1Q63594390-08208F55-1612-4683-B4B5-25E194252743Q63600503-0A635B29-E326-4C50-BB92-C5A028E3F5B3Q63813372-F37220AB-13FB-4F7C-905E-555D7987B192Q87932844-00B150AA-D40F-4E51-A95B-2DDB21FA978A
P4844
Q22305855-16210CBB-75AA-4C22-8990-EBD6C242BC84Q26995834-C7CC27DB-0501-40D3-9569-A1C628CF9F31Q33659004-4AF6DFBD-5E2D-499F-94DE-D9EE38D2981CQ34295181-BBAA4642-81BA-41FC-8EDD-867260D88114Q34548528-E5240444-DAF7-4B10-A447-EFCCCE8E3428Q36866954-80E16731-30BE-49D3-A7B5-93DE30F01AA1Q38144973-54E1E088-604D-4F51-9EC5-90A4EF5991D8Q38193099-5E11DB41-0112-4E1C-A983-2A8A510984CDQ38202205-0C61AEE8-3C93-4B17-B7EB-126180161E04Q38209439-DB3EAC72-CD94-483C-95C9-A96103288CB1Q38226598-93CDA197-812C-42B4-902E-08D768945497Q38229893-90BDE968-0FC7-4A00-8853-850906822D38Q38445531-01A93539-7643-4E36-86E1-9C8A98888AECQ38989574-99D20573-74C9-4F51-BEF4-1D0A69B52349Q43550280-05A1BD67-D93A-46F2-99ED-66775AD49B29Q44572083-D9AFD649-4EE9-4905-8F05-77FDF1555C9AQ45329526-6880DCE8-FA06-4279-9F94-4E8DD646D545Q53280162-89C6513D-EE8A-4E41-A952-231BE45180DFQ84978595-6FAB559C-ABD6-4D3D-B181-F671BBC8D55EQ87431059-E13F6DE7-09A2-4B7A-B1D7-723A79E72112Q93610233-C1EDE1DA-C415-46C8-A3F5-B358C714B3A1
P921
description
Phosphodiesterase-Hemmer zur Behandlung von Psoriasisarthritis
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Apremilast
@de
Apremilast
@nl
Apremilast
@sh
Apremilast
@sr
Apremilast
@vi
apremilast
@en
apremilast
@nn
apremilast
@pt
aprémilast
@fr
Апремиласт
@ru
type
label
Apremilast
@de
Apremilast
@nl
Apremilast
@sh
Apremilast
@sr
Apremilast
@vi
apremilast
@en
apremilast
@nn
apremilast
@pt
aprémilast
@fr
Апремиласт
@ru
altLabel
Apremilast
@en
Apremilastum
@en
Aprémilast
@en
CC 10004
@en
CC-10004
@en
CC10004
@en
N-{2-[(1S)-1-(3-Ethoxy-4-metho ...... dro-1H-isoindol-4-yl}acetamide
@en
Otezla®
@en
prefLabel
Apremilast
@de
Apremilast
@nl
Apremilast
@sh
Apremilast
@sr
Apremilast
@vi
apremilast
@en
apremilast
@nn
apremilast
@pt
aprémilast
@fr
Апремиласт
@ru